Mineralys Therapeutics (MLYS) Research & Development (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Research & Development data on file, last reported at $24.4 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 35.68% year-over-year to $24.4 million; the trailing twelve-month figure through Mar 2026 stood at $118.5 million (down 32.56% YoY), and the FY2025 full-year result was $132.0 million, down 21.69% from the prior year.
• Research & Development steadied at $24.4 million in Q1 2026, from $24.4 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $54.0 million in Q3 2024 to a low of $5.6 million in Q2 2022.
• A 5-year average of $24.8 million and a median of $24.4 million in 2026 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 271.33% in 2023 and slumped 45.25% in 2025, its largest moves.
• Tracing MLYS's Research & Development over 5 years: stood at $7.8 million in 2022, then jumped by 202.95% to $23.7 million in 2023, then jumped by 88.17% to $44.6 million in 2024, then tumbled by 45.25% to $24.4 million in 2025, then slipped by 0.15% to $24.4 million in 2026.
• Business Quant data shows MLYS's Research & Development at $24.4 million in Q1 2026, $24.4 million in Q4 2025, and $31.4 million in Q3 2025.